# Mira Pharmaceuticals, Inc.: overview MIRA · Nasdaq · CIK 1904286 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/mira.md) · [Financials](/companies/mira/financials.md) · [Filings](/companies/mira/filings.md) · [Insiders](/companies/mira/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.14)](/filings/0001493152-25-022112.md) | not reported | [(0.11)](/filings/0001493152-26-023005.md) | [(0.09)](/filings/0001493152-26-037366.md) | [(1.18)](/filings/0001493152-25-022112.md) | not reported | [(0.03)](/filings/0001493152-26-023005.md) | [(0.03)](/filings/0001493152-26-037366.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.40)](/filings/0001493152-24-012141.md) | [(0.85)](/filings/0001641172-25-001183.md) | [(0.51)](/filings/0001493152-26-014001.md) | [(1.35)](/filings/0001493152-26-014001.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mira/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $712.0k | 751,801 | | Added +57,889 | | [Cross Staff Investments Inc](/funds/1900406.md) | 2026-06-30 | $340.2k | 359,401 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $287.6k | 303,882 | | Added +12,992 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $231.5k | 244,622 | | Added +132,276 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $161.6k | 170,668 | | Added +1,185 | | [CAPTRUST FINANCIAL ADVISORS](/funds/1512024.md) | 2026-06-30 | $85.8k | 90,645 | | New +90,645 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $64.1k | 67,735 | | Added +37 | | [FIRST AMERICAN BANK](/funds/1291422.md) | 2026-06-30 | $56.8k | 60,000 | | Unchanged | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $50.3k | 53,189 | | Added +18,122 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $46.5k | 49,100 | | Unchanged | ## Recent filings [All 197 filings](/companies/mira/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 12:00 ET | [8-K](/filings/0001493152-26-048022.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-048022 | | 2026-09-17 | 12:30 ET | [8-K](/filings/0001493152-26-043051.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-043051 | | 2026-09-16 | 20:30 ET | [8-K](/filings/0001493152-26-042927.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-042927 | | 2026-09-01 | 12:00 ET | [8-K](/filings/0001493152-26-040930.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-040930 | | 2026-08-12 | 20:17 ET | [10-Q](/filings/0001493152-26-037366.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037366 | | 2026-08-06 | 12:00 ET | [8-K](/filings/0001493152-26-036262.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036262 | | 2026-07-31 | 21:00 ET | [8-K](/filings/0001493152-26-035665.md) | 3.01 Delisting notice | 0001493152-26-035665 | | 2026-07-28 | 21:00 ET | [DEF 14A](/filings/0001493152-26-035027.md) | Proxy statement, period 2026-07-28 | 0001493152-26-035027 | | 2026-07-10 | 12:00 ET | [8-K](/filings/0001493152-26-032777.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-032777 | | 2026-07-06 | 13:00 ET | [8-K](/filings/0001493152-26-032091.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-032091 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014001.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1904286 - Tickers: MIRA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: FL - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.